Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $14.67 million
- Outstanding Shares: 13,586,000
Average Prices:- 50 Day Moving Avg: $1.38
- 200 Day Moving Avg: $1.82
- 52 Week Range: $1.01 - $7.15
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.01) per share
- Price / Book: -107.00
Profitability:- EBIDTA: ($12,480,000.00)
- Return on Equity: -552.76%
- Return on Assets: -107.04%
Debt:- Debt-to-Equity Ratio: -16.69%
- Current Ratio: 0.02%
- Quick Ratio: 0.02%
Misc:- Average Volume: 617,316 shs.
- Beta: 2.1
- Short Ratio: 6.84
Frequently Asked Questions for Immune Pharmaceuticals (NASDAQ:IMNP)
What is Immune Pharmaceuticals' stock symbol?
Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."
How were Immune Pharmaceuticals' earnings last quarter?
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) posted its quarterly earnings results on Monday, August, 15th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). View Immune Pharmaceuticals' Earnings History.
When will Immune Pharmaceuticals make its next earnings announcement?
Where is Immune Pharmaceuticals' stock going? Where will Immune Pharmaceuticals' stock price be in 2017?
1 analysts have issued 1-year price objectives for Immune Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Immune Pharmaceuticals' stock price to reach $3.00 in the next year. View Analyst Ratings for Immune Pharmaceuticals.
Who are some of Immune Pharmaceuticals' key competitors?
Some companies that are related to Immune Pharmaceuticals include Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR), Galena Biopharma (GALE), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), CoLucid Pharmaceuticals (CLCD), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK), Innocoll Holdings PLC (INNL), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Sagent Pharmaceuticals (SGNT) and Santarus (SNTS).
Who are Immune Pharmaceuticals' key executives?
Immune Pharmaceuticals' management team includes the folowing people:
- Elliot M. Maza J.D., CPA, Interim Chief Executive Officer, Director
- John Militello CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller
- Anthony Fiorino M.D. Ph.D., Chief Operating Officer, Chief Medical Officer
- Cameron Durrant M.D., Lead Independent Director
- Daniel G. Teper Pharm.D., Director
- John A Neczesny, Independent Director
- Jeffrey Paley M.D., Independent Director
Who owns Immune Pharmaceuticals stock?
Immune Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.28%) and Susquehanna International Group LLP (0.69%). Company insiders that own Immune Pharmaceuticals stock include Daniel Gedeon Teper, Daniel Kazado and Monica E Luchi. View Institutional Ownership Trends for Immune Pharmaceuticals.
Who sold Immune Pharmaceuticals stock? Who is selling Immune Pharmaceuticals stock?
Who bought Immune Pharmaceuticals stock? Who is buying Immune Pharmaceuticals stock?
Immune Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. Company insiders that have bought Immune Pharmaceuticals stock in the last two years include Daniel Gedeon Teper, Daniel Kazado and Monica E Luchi. View Insider Buying and Selling for Immune Pharmaceuticals.
How do I buy Immune Pharmaceuticals stock?
Shares of Immune Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Pharmaceuticals' stock price today?
One share of Immune Pharmaceuticals stock can currently be purchased for approximately $1.07.
MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $3.00 (180.37% upside) |
Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/3/2016 | FBR & Co | Reiterated Rating | Outperform | $3.00 | N/A |  |
| 5/16/2016 | Chardan Capital | Reiterated Rating | Buy | | N/A | |
| 4/4/2016 | Roth Capital | Reiterated Rating | Buy | | N/A | |
(Data available from 9/19/2015 forward)
Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)Earnings History by Quarter for Immune Pharmaceuticals (NASDAQ IMNP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/17/2017 | | | | | | | | |
| 8/15/2016 | Q2 | ($0.13) | ($0.13) | | | View | N/A | |
| 5/16/2016 | Q116 | ($0.15) | ($0.17) | | | View | N/A | |
| 3/30/2016 | Q4 | ($0.16) | ($0.27) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.18) | ($0.33) | $15.00 million | | View | Listen | |
| 8/17/2015 | Q215 | ($0.19) | ($0.12) | | | View | N/A | |
| 5/18/2015 | Q1 | ($0.20) | ($0.15) | | | View | N/A | |
| 4/15/2015 | Q4 2014 | ($0.37) | ($0.34) | | | View | N/A | |
| 8/14/2014 | Q2 2014 | ($0.21) | ($0.27) | | | View | N/A | |
| 5/21/2014 | Q1 2014 | ($0.15) | ($0.35) | | | View | N/A | |
| 4/10/2014 | Q4 2013 | ($0.15) | ($0.29) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Immune Pharmaceuticals (NASDAQ:IMNP)Insider Ownership Percentage: 6.74%
Institutional Ownership Percentage: 3.39%
Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/4/2017 | Daniel Kazado | Director | Buy | 76,503 | $0.19 | $14,535.57 | |
| 12/16/2016 | Daniel Kazado | Director | Buy | 161,377 | $0.19 | $30,661.63 | |
| 8/4/2016 | Daniel Gedeon Teper | CEO | Buy | 937,500 | $0.38 | $356,250.00 | |
| 8/4/2016 | Daniel Kazado | Director | Buy | 666,667 | $0.45 | $300,000.15 | |
| 8/4/2016 | Monica E Luchi | CMO | Buy | 777,778 | $0.45 | $350,000.10 | |
| 1/26/2016 | Daniel Gedeon Teper | CEO | Buy | 42,000 | $0.59 | $24,780.00 | |
| 1/19/2016 | Daniel Gedeon Teper | CEO | Buy | 44,200 | $0.57 | $25,194.00 | |
| 1/12/2016 | Daniel Gedeon Teper | CEO | Buy | 39,400 | $0.62 | $24,428.00 | |
| 1/5/2016 | Daniel Gedeon Teper | CEO | Buy | 62,000 | $0.81 | $50,220.00 | |
| 12/7/2015 | Daniel Gedeon Teper | CEO | Buy | 65,400 | $0.76 | $49,704.00 | |
| 12/7/2015 | Daniel Kazado | Director | Buy | 150,000 | $0.78 | $117,000.00 | |
| 10/26/2015 | Daniel Gedeon Teper | CEO | Buy | 18,400 | $1.36 | $25,024.00 | |
| 10/19/2015 | Daniel Gedeon Teper | CEO | Buy | 18,600 | $1.34 | $24,924.00 | |
| 10/12/2015 | Daniel Gedeon Teper | CEO | Buy | 19,000 | $1.30 | $24,700.00 | |
| 10/5/2015 | Daniel Gedeon Teper | CEO | Buy | 40,700 | $1.23 | $50,061.00 | |
| 9/14/2015 | Rene Pierre Azria | Director | Buy | 50,000 | $1.48 | $74,000.00 | |
| 9/1/2015 | Daniel Gedeon Teper | CEO | Buy | 7,569 | $1.29 | $9,764.01 | |
(Data available from 1/1/2013 forward)
Headline Trends for Immune Pharmaceuticals (NASDAQ:IMNP)
Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
| Source: |
|
| Date | Headline |
|---|
 | Immune Pharma (IMNP) Receives NASDAQ Letter
www.streetinsider.com - August 31 at 7:53 PM |
 | Immune Pharmaceuticals Provides R&D and Business Update and ... - Business Wire (press release)
www.businesswire.com - August 30 at 2:08 AM |
| Immune Pharma (IMNP) Receives NASDAQ Letter - StreetInsider.com
www.streetinsider.com - August 30 at 2:08 AM |
 | Immune Pharmaceuticals Receives NASDAQ Letter
finance.yahoo.com - August 30 at 2:08 AM |
 | Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
globenewswire.com - August 24 at 7:57 AM |
| Immune Pharma (IMNP) Appoints Tony Fiorino, MD, PhD as CMO and COO - StreetInsider.com
www.streetinsider.com - August 15 at 3:25 AM |
| Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer
finance.yahoo.com - August 14 at 10:23 PM |
| CYTOVIA Inc, IMMUNE Pharma's Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic ... - Business Wire (press release)
www.businesswire.com - August 9 at 8:08 PM |
| CYTOVIA Inc, IMMUNE Pharma’s Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent
finance.yahoo.com - August 9 at 8:08 PM |
| CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces ... - Business Wire (press release)
www.businesswire.com - August 8 at 7:33 PM |
| CYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting ...
www.businesswire.com - August 7 at 7:19 PM |
| CYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML)
finance.yahoo.com - August 7 at 7:19 PM |
 | Contrasting Theravance Biopharma (TBPHV) and Immune Pharmaceuticals (IMNP)
www.americanbankingnews.com - August 1 at 10:26 PM |
| SCYNEXIS (SCYX) versus Immune Pharmaceuticals (IMNP) Financial Analysis
www.americanbankingnews.com - August 1 at 8:04 AM |
| Cambrex Corporation (CBM) vs. Immune Pharmaceuticals (NASDAQ:IMNP) Head-To-Head Review
www.americanbankingnews.com - July 24 at 10:18 PM |
 | BRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia - Reuters
www.reuters.com - July 19 at 8:56 PM |
| Immune Pharma (IMNP) Provides Update on Spin-off of Cytovia - StreetInsider.com
www.streetinsider.com - July 19 at 8:56 PM |
| Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
finance.yahoo.com - July 19 at 8:56 PM |
| IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting ... - Business Wire (press release)
www.businesswire.com - July 15 at 2:13 AM |
| IMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other ...
www.businesswire.com - July 14 at 3:49 AM |
| IMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1
finance.yahoo.com - July 14 at 3:49 AM |
| Immune Pharma (IMNP) Subsidiary Enters into Definitive Agreement with Pint Pharma for Licensing and ... - StreetInsider.com
www.streetinsider.com - July 13 at 3:10 AM |
| Cytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene ® in Latin ...
www.businesswire.com - July 11 at 11:50 PM |
| Immune Pharma (IMNP) Subsidiary Enters into Definitive Agreement with Pint Pharma for Licensing and Commercialization of Ceplene in Latin America
www.streetinsider.com - July 11 at 11:50 PM |
| Cytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America
finance.yahoo.com - July 11 at 11:50 PM |
| IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal
finance.yahoo.com - July 6 at 5:52 AM |
| Immune Pharma (IMNP) Subsidiary, Cytovia, Announces Ceplene Licensing & Commercialization Agreement for Latin America
www.streetinsider.com - July 2 at 12:19 AM |
| Immune Pharma (IMNP) Subsidiary, Cytovia, Announces Ceplene Licensing & Commercialization Agreement for Latin ... - StreetInsider.com
www.streetinsider.com - June 30 at 7:57 PM |
| Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America
finance.yahoo.com - June 30 at 12:10 AM |
 | Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic ... - PR Newswire (press release)
www.prnewswire.com - June 20 at 11:59 PM |
| Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)
finance.yahoo.com - June 20 at 6:48 PM |
| Immune Receives NASDAQ Compliance Letter
finance.yahoo.com - June 19 at 12:22 PM |
| Immune Pharma (IMNP) to Regain Worldwide Rights for Ceplene - StreetInsider.com
www.streetinsider.com - June 17 at 6:26 PM |
| Immune Pharma (IMNP) to Regain Worldwide Rights for Ceplene
www.streetinsider.com - June 16 at 5:07 AM |
| Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene
finance.yahoo.com - June 16 at 5:07 AM |
| Immune Pharmaceuticals (IMNP) vs. Bristol-Myers Squibb Company (BMY) Critical Survey
www.americanbankingnews.com - June 15 at 2:08 PM |
| Research Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera ... - PR Newswire (press release)
www.prnewswire.com - June 2 at 8:08 AM |
| Immune Pharma (IMNP) Regains Compliance with Min. Bid Price Rule Citing Letter from Nasdaq
www.streetinsider.com - May 27 at 4:43 AM |
| Immune Receives Nasdaq Letters
finance.yahoo.com - May 26 at 6:38 PM |
| Immune Pharmaceuticals Inc (IMNP) Short Interest Up 35.8% in April
www.americanbankingnews.com - May 13 at 7:12 AM |
| Short Interest in Immune Pharmaceuticals Inc (IMNP) Expands By 6.4%
www.americanbankingnews.com - May 9 at 7:12 AM |
| Immune Pharma (IMNP) Announces Private Placement of up to $3.4 ... - StreetInsider.com
www.streetinsider.com - May 4 at 6:03 PM |
| Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million
finance.yahoo.com - May 4 at 6:03 PM |
| Immune Pharma (IMNP) Announces Corporate Restructuring, CEO to Resign
www.streetinsider.com - April 24 at 5:33 PM |
| Immune Receives Nasdaq Letter
finance.yahoo.com - April 24 at 9:31 AM |
| Immune Pharmaceuticals Announces Corporate Restructuring
finance.yahoo.com - April 24 at 9:30 AM |
| Immune Pharma shares tumble 9% premarket as it unveils restructuring
finance.yahoo.com - April 24 at 9:30 AM |
| Somewhat Favorable Media Coverage Somewhat Likely to Affect Immune Pharmaceuticals (IMNP) Stock Price
www.americanbankingnews.com - April 22 at 11:59 AM |
| Today's Research Reports on Stocks to Watch: Aurinia ... - Yahoo Finance
finance.yahoo.com - April 22 at 8:10 AM |
| Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals
finance.yahoo.com - April 21 at 10:43 AM |
Immune Pharmaceuticals (IMNP) Chart for Tuesday, September, 19, 2017
